Dithranol irritation in psoriasis treatment: a study of 68 inpatients

J Eur Acad Dermatol Venereol. 2005 Mar;19(2):176-9. doi: 10.1111/j.1468-3083.2005.01093.x.

Abstract

The irritant response of perilesional skin is a serious limitation of dithranol therapy in psoriasis. No data are available on the actual prevalence and severity of irritation during 24-h dithranol treatment in an inpatient setting. Using a retrospective analysis of 68 patients with psoriasis visiting our inpatient department for dithranol treatment, the occurrence of dithranol irritation was studied. We found a relatively high frequency of dithranol irritation. Furthermore, most irritation occurs at the start of the therapy with relatively low concentrations.

MeSH terms

  • Administration, Topical
  • Adult
  • Aged
  • Anthralin / adverse effects*
  • Anthralin / therapeutic use*
  • Anti-Inflammatory Agents / adverse effects*
  • Anti-Inflammatory Agents / therapeutic use*
  • Female
  • Humans
  • Inpatients
  • Male
  • Middle Aged
  • Psoriasis / drug therapy*
  • Retrospective Studies
  • Time Factors

Substances

  • Anti-Inflammatory Agents
  • Anthralin